POINTED: Post-COVID-19 Monitoring in Routine Health Insurance Data
Study Details
Study Description
Brief Summary
The SARS-CoV-2 infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and which symptoms are related to it. The aim of the study is to monitor the onset of these conditions in a large observational study consisting of German health insurance data.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand the prevalence and variety of Post-COVID a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID.
The basic question concerns the burden of the Post-COVID condition. The study investigate which symptoms are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in the subgroup of children and adolescents and those who have been hospitalized due to the virus infection.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Adults 145184 patients with COVID-19 over 17 years of age. |
Other: Exposed to a SARS-CoV-2 infection
The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
|
| Children and adolescents 11950 patients with COVID-19 under 18 years of age. |
Other: Exposed to a SARS-CoV-2 infection
The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
|
Outcome Measures
Primary Outcome Measures
- Incidence of abdominal pain [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of abdominal pain recorded in outpatient or inpatient setting
- Incidence of acute pain [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of acute pain recorded in outpatient or inpatient setting
- Incidence of adjustment disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of adjustment disorder recorded in outpatient or inpatient setting
- Incidence of anuria/oliguria [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of anuria/oliguria in outpatient or inpatient setting
- Incidence of anxiety disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of anxiety disorder in outpatient or inpatient setting
- Incidence of arthritides [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of arthritides in outpatient or inpatient setting
- Incidence of ascites [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of ascites in outpatient or inpatient setting
- Incidence of behavioral symptoms [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of behavioral symptoms in outpatient or inpatient setting
- Incidence of cachexia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of cachexia in outpatient or inpatient setting
- Incidence of carditis due to viruses [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of carditis due to viruses in outpatient or inpatient setting
- Incidence of changes in bowel habits [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of changes in bowel habits due to viruses in outpatient or inpatient setting
- Incidence of chronic fatigue syndrome [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of chronic fatigue syndrome in outpatient or inpatient setting
- Incidence of cognitive function impairment [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of cognitive function impairment in outpatient or inpatient setting
- Incidence of concentration impairment/concentration deficit [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of concentration impairment/concentration deficit in outpatient or inpatient setting
- Incidence of cough [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of cough in outpatient or inpatient setting
- Incidence of COVID toe [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of COVID toe in outpatient or inpatient setting
- Incidence of depression [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of depression in outpatient or inpatient setting
- Incidence of developmental delay [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of developmental delay in outpatient or inpatient setting
- Incidence of disorientation [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of disorientation in outpatient or inpatient setting
- Incidence of dysgeusia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of dysgeusia in outpatient or inpatient setting
- Incidence of dyslexia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of dyslexia in in outpatient or inpatient setting
- Incidence of dysmenorrhea [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of dysmenorrhea in outpatient or inpatient setting
- Incidence of dysphagia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of dysphagia in outpatient or inpatient setting
- Incidence of dyspnea [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of dyspnea in outpatient or inpatient setting
- Incidence of dysuria [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of dysuria in outpatient or inpatient setting
- Incidence of emotional and behavioral disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of emotional and behavioral disorder in outpatient or inpatient setting
- Incidence of epistaxis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of epistaxis in outpatient or inpatient setting
- Incidence of eye pain [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of eye pain in outpatient or inpatient setting
- Incidence of facial nerve paralysis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of facial nerve paralysis in outpatient or inpatient setting
- Incidence of fever [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of fever in outpatient or inpatient setting
- Incidence of flatulence [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of flatulence in outpatient or inpatient setting
- Incidence of gangrene [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of gangrene in outpatient or inpatient setting
- Incidence of general symptoms [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of general symptoms in outpatient or inpatient setting
- Incidence of hair loss [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hair loss in outpatient or inpatient setting
- Incidence of headache [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of headache in outpatient or inpatient setting
- Incidence of hearing loss/tinnitus [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hearing loss/tinnitus in outpatient or inpatient setting
- Incidence of heart failure [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of heart failure in outpatient or inpatient setting
- Incidence of heart murmurs [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of heart murmurs in outpatient or inpatient setting
- Incidence of heartburn [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of heartburn in outpatient or inpatient setting
- Incidence of hemorrhage [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hemorrhage in outpatient or inpatient setting
- Incidence of hepatomegaly and splenomegaly [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hepatomegaly and splenomegaly in outpatient or inpatient setting
- Incidence of hoarseness [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hoarseness in outpatient or inpatient setting
- Incidence of hyperhidrosis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hyperhidrosis in outpatient or inpatient setting
- Incidence of hypotension [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of hypotension in outpatient or inpatient setting
- Incidence of impaired balance [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of impaired balance in outpatient or inpatient setting
- Incidence of joint pain [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of joint pain in outpatient or inpatient setting
- Incidence of loss of appetite [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of Loss of appetite in outpatient or inpatient setting
- Incidence of lymphadenopathy [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of lymphadenopathy in outpatient or inpatient setting
- Incidence of Malaise/fatigue/exhaustion [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of Malaise/fatigue/exhaustion in outpatient or inpatient setting
- Incidence of memory impairment [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of memory impairment in outpatient or inpatient setting
- Incidence of meningismus [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of meningismus in outpatient or inpatient setting
- Incidence of mood disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of mood disorder in outpatient or inpatient setting
- Incidence of movement disorders [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of movement disorders in outpatient or inpatient setting
- Incidence of myalgia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of myalgia in outpatient or inpatient setting
- Incidence of myocardial infarction [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of myocardial infarction in outpatient or inpatient setting
- Incidence of myocarditis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of myocarditis in outpatient or inpatient setting
- Incidence of nausea [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of nausea in outpatient or inpatient setting
- Incidence of neurasthenia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of neurasthenia in outpatient or inpatient setting
- Incidence of neurological manifestation of Post-COVID [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of Neurological manifestation of Post-COVID in outpatient or inpatient setting
- Incidence of obsessive-compulsive disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of obsessive-compulsive disorder in outpatient or inpatient setting
- Incidence of oedema [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of oedema in outpatient or inpatient setting
- Incidence of other cardiac arrhythmias [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of other cardiac arrhythmias in outpatient or inpatient setting
- Incidence of other coordination disorders/ataxia [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of other coordination disorders/ataxia in outpatient or inpatient setting
- Incidence of other symptoms of the urinary system [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of other symptoms of the urinary system in outpatient or inpatient setting
- Incidence of pain, not elsewhere classified [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of pain, not elsewhere classified in outpatient or inpatient setting
- Incidence of paresis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of paresis in outpatient or inpatient setting
- Incidence of paresthesia of skin [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of paresthesia of skin in outpatient or inpatient setting
- Incidence of pathological findings from male genital tract [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of pathological findings from male genital tract in outpatient or inpatient setting
- Incidence of pathological lung findings [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of pathological lung findings from male genital tract in outpatient or inpatient setting
- Incidence of pathological reflexes [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of pathological reflexes in outpatient or inpatient setting
- Incidence of pericarditis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of pericarditis in outpatient or inpatient setting
- Incidence of polyuria [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of polyuria in outpatient or inpatient setting
- Incidence of Post-COVID [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of Post-COVID in outpatient or inpatient setting
- Incidence of pulmonary embolism [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of pulmonary embolism in outpatient or inpatient setting
- Incidence of rash [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of rash in outpatient or inpatient setting
- Incidence of respiratory insufficiency [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of respiratory insufficiency in outpatient or inpatient setting
- Incidence of seizures [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of seizures in outpatient or inpatient setting
- Incidence of sensation and perception disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of sensation and perception disorder in outpatient or inpatient setting
- Incidence of shock [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of shock in outpatient or inpatient setting
- Incidence of sinus vein thrombosis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of sinus vein thrombosis in outpatient or inpatient setting
- Incidence of sleep disorders [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of sleep disorders in outpatient or inpatient setting
- Incidence of somatization disorder [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of somatization disorder in outpatient or inpatient setting
- Incidence of somnolence [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of somnolence in outpatient or inpatient setting
- Incidence of sopor/coma [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of sopor/coma in outpatient or inpatient setting
- Incidence of speech and language disorders [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of speech and language disorders in outpatient or inpatient setting
- Incidence of stroke [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of stroke in outpatient or inpatient setting
- Incidence of subcutaneous nodules [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of subcutaneous nodules in outpatient or inpatient setting
- Incidence of syncope [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of syncope in outpatient or inpatient setting
- Incidence of tetany [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of tetany in outpatient or inpatient setting
- Incidence of throat/chest pain [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of throat/chest pain in outpatient or inpatient setting
- Incidence of thrombosis [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of thrombosis in outpatient or inpatient setting
- Incidence of urethral discharge [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of urethral discharge in outpatient or inpatient setting
- Incidence of urinary retention [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of urinary retention in outpatient or inpatient setting
- Incidence of vertigo [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of vertigo in outpatient or inpatient setting
- Incidence of visual disturbances [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of visual disturbances in outpatient or inpatient setting
- Incidence of weight gain/loss, eating disorders [At least 12 weeks after the infection by SARS-CoV-2]
Incidence of a diagnosis of weight gain/loss, eating disorders in outpatient or inpatient setting
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least one outpatient or inpatient diagnosis of COVID-19 with laboratory detection of the virus (ICD-10: U07.1!)
-
Continuously insured with the respective health insurance between 2019-01-01/birth and 2020-12-31/death
Exclusion Criteria:
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Center for Evidence-Based Healthcare | Dresden | Saxony | Germany | 01307 |
Sponsors and Collaborators
- Technische Universität Dresden
- InGef - Institut für angewandte Gesundheitsforschung Berlin GmbH
- BARMER Institut für Gesundheitssystemforschung (bifg)
- AOK Bayern - Die Gesundheitskasse
- AOK PLUS
- DAK Gesundheit
- Techniker Krankenkasse
Investigators
- Principal Investigator: Falko Tesch, Center for Evidence-Based Healthcare, Technische Universität Dresden
- Study Director: Jochen Schmitt, MD, MPH, Center for Evidence-Based Healthcare, Technische Universität Dresden
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- POINTED